Recursion Pharmaceuticals is trading 10.91% up at $3.54, primarily amid biotech-sector strength; no clear company-specific announcement was identified for September 17, 2026.
- Biotech is up 2.55%, supported by stronger pharmaceutical demand, increased research investment, improved funding conditions, and merger optimism.
- Broader risk appetite is supporting growth stocks, with the Nasdaq Composite up 1.60%.